Latest Partnerships News

Fonterra’s FY26 Q3 results show a $1.8 billion operating profit, up $103 million year-on-year, prompting an uplift and narrowing of earnings guidance. The co-op also announced a stable 2026/27 Farmgate Milk Price forecast amid rising milk collections and ongoing geopolitical risks.

Klevo Rewards takes a major step in building a regulated crypto-financial platform by partnering with Bybit and proposing key acquisitions to expand Fly Wallet’s digital asset and credit capabilities.

Delorean Corporation has closed its Share Purchase Plan, raising $750,000 through the issue of over 8.3 million shares at $0.09 each, supplementing earlier strategic funding from LMS Energy.

Cosmos Exploration has finalised its acquisition of EAU Lithium, issuing 108 million shares to former EAU shareholders and appointing James Durrant as Chairman to drive its Bolivian lithium ambitions.

Dicker Data has outperformed its FY25 guidance, delivering a 14.9% jump in gross revenue to $3.876 billion, fuelled by AI deals and infrastructure refreshes. The company’s FY26 outlook anticipates continued momentum in AI and data centre projects despite pricing pressures.

Straker Limited resumes ASX trading after suspending shares due to transaction anomalies at its US subsidiary. The company maintains normal operations while cooperating with US authorities.

Vista Group International has secured a five-year contract to transition Cinemex’s Mexican cinema circuit back to its technology platform, expanding on last year’s US rollout success.

Australian Vintage Limited has locked in a $128 million refinancing deal extending to 2029 and reported a significant cash flow turnaround in FY26, driven by innovation and strategic acquisitions.

International Graphite Limited and Italian chemical producer Alkeemia have formalised a joint venture to develop a major graphite processing facility in Porto Marghera, Italy, targeting 15,000 tonnes per year by 2029 with first production expected in 2027.

Recce Pharmaceuticals has signed a non-binding term sheet with a major Middle Eastern pharma player for exclusive rights to commercialise its R327 Topical Gel across the MENA region, targeting a high diabetes burden market.

Neurizon Therapeutics has boosted the participant count in its HEALEY ALS Platform Trial Regimen I from 160 to 240, capitalising on faster enrolment and philanthropic support to maintain costs and accelerate topline results to early Q3 2027.

Harvest Technology Group secures a A$6.5 million two-tranche placement to fund its defence strategy, expand Nodestream, and strengthen its balance sheet ahead of key growth initiatives.